HealthTell Inc., an Arizona State University spinout, has raised $4 million to commercialize a test for lung, breast, prostate and colorectal cancer. The Chandler, Ariz.-based startup is working to develop a variety of health monitoring tools to check the status of patients who are battling any of 30 illnesses, ranging from cancer to infectious disease.
According to a statement:
Instead of trying to measure the pathogen directly, the company measures the body’s unique response (its “immunosignature”) to a given disease or disease state. By understanding what each immunosignature means and how it changes over time, HealthTell can provide a broad menu of highly accurate tests that are capable of detecting diseases much earlier and less invasively than is possible today.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The startup has gotten the attention of the US military, too:
HealthTell is also supplying chips for two ASU projects funded by the U.S. Department of Defense and its Defense Threat Reduction Agency (DTRA). DTRA is interested in using the diagnostic test to check the health of soldiers in the field. HealthTell also won the 2012 Governor’s Award for Innovation in Arizona.